NEWS

We Work For Health released the following statement on the Trump Administration’s April 15 executive order regarding the Inflation...

Small-molecule drug investment has fallen 68%—and 74% for diseases mainly affecting Medicare patients—since the IRA was introduced FOR...

The lead sponsors of the Ensuring Pathways to Innovative Cures (EPIC) Act addressed a room full of Congressional office employees and...

Learn about the Inflation Reduction Act—and how it’s threatening America’s biopharmaceutical ecosystem and our nation’s Medicare-aged...

Innovation often comes in increments. The first smartphones could not record video or take front-facing photos, and there certainly was...

A new report highlights the significant investments and economic impact generated by clinical trials funded by the biopharmaceutical...

Legislation would address the “pill penalty” and strengthen U.S. leadership in pharmaceutical innovation. WASHINGTON, D.C. (March 6,...

Healthcare costs continue to be a significant concern for Americans. While policies like government price controls under the Inflation...

Small-molecule drugs, which typically come in pill or tablet form, have long been the backbone of modern medicine, treating everything...

Bipartisan legislation would correct the IRA’s “pill penalty,” which will have a chilling effect on the prescription drug ecosystem...

We Work For Health Executive Director Dan Leonard's recently wrote a letter to the White House, encouraging a pause in the implementation...

FOR IMMEDIATE RELEASE JAN. 17, 2025   WASHINGTON, DC (Jan. 17, 2025) – The Centers for Medicare and Medicaid Services’ (CMS) announcement...

Research firm Vital Transformation is preparing a new analysis about the impacts of the Inflation Reduction Act on biopharma investment,...

At We Work For Health (WWFH), our commitment to fostering health equity across the nation goes beyond advocacy—it extends to tangible,...

The biopharmaceutical industry is the backbone of America's innovative economy, supporting more than 4.9 million jobs across the United...

We Work For Health Executive Director Dan Leonard released the following statement in support of recently introduced legislation that...

As Congress returned to Washington, the Senate Judiciary Committee held a full committee hearing  to consider a number of critical bills...

Washington, DC  – New research contradicts promises of savings at the pharmacy counter for Medicare beneficiaries from the Inflation...

New research from the IQVIA Institute for Human Data Science further confirms what We Work For Health (WWFH) and others have warned...

The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, profoundly changed the...

Dear Chairman Sanders, Ranking Member Cassidy, and Members of the Committee:  The American medical innovation infrastructure that has...

As healthcare access and costs continue to dominate political conversations, the flaws in the Inflation Reduction Act are becoming...

In 1984, the Hatch-Waxman Act – formally known as the bipartisan Drug Price Competition and Patent Term Restoration Act  – established a...

During a recent We Work For Health roundtable with California Rep. Scott Peters, leaders across patient advocacy, biopharma, labor,...

While the 1980s is best remembered for its questionable fashion and cultural influence, two critical policies from early in the decade...

American innovation depends on a strong, robust intellectual property system that allows health care advances to save and enhance lives....

We Work For Health recently unveiled a new set of one-page resources designed to highlight the significant impact of the...

A version of this blog originally published as an op-ed in The Center Square in Arizona. We're sharing it here with additional updates...

Aug. 15, 2024 FOR IMMEDIATE RELEASE WASHINGTON, D.C. – We Work For Health Executive Director Dan Leonard issued the following statement...

The Biden administration this week is expected to claim victory on its stated goal of lowering drug prices for seniors. While the...

By Dan Leonard, WWFH Executive Director Intellectual property (IP) plays a crucial role in the success of the pharmaceutical and biotech...

On Monday, the Centers for Medicare and Medicaid Services (CMS) announced 2025 premiums for Medicare Part D plans will increase again....

Meena Seshamani, M.D., Ph.D. CMS Deputy Administrator and Director of the Center for Medicare Centers for Medicare & Medicaid Services...

During an event on Capitol Hill this week, California Rep. Scott Peters highlighted a graphic that clearly illustrates the distorted...

Despite the significant demand for effective non-opioid medications for the treatment of pain, a recent report from the Pioneer Institute...

SAN DIEGO – At a We Work For Health roundtable on June 20, the organization and its partners honored Rep. Scott Peters (CA-50) with the...

The National Institute of Standards and Technology (NIST) may soon finalize its controversial proposal to expand the scope of the...

For Immediate Release June 5, 2024 Contact: Lisa Glass 512-695-3569 / lglass@rosscomm.com New Data Reveals Strong Economic Impact of...

This week, the largest not-for-profit health insurance provider in Missouri, Blue KC, announced it will leave the Medicare Advantage...

The Centers for Medicare & Medicaid Services (CMS) recently released a final rule allowing Medicare Advantage and Part D health plans to...

FOR IMMEDIATE RELEASE April 26, 2024 WASHINGTON, D.C. – We Work For Health Executive Director Dan Leonard issued the following statement...

Today, President Biden highlighted the administration’s current and future efforts to lower healthcare costs. The good news is recent...

We Work For Health recently convened a conversation to explore the impact policy decisions have on the biopharmaceutical industry and...

We Work For Health recently released new employment, vendor and supplier expenditure data that showcases the vital contributions of these...

During his State of the Union address Thursday night, President Biden called for Congress to expand the Inflation Reduction Act to...

On Feb. 29, the House Energy and Commerce Subcommittee on Health held a hearing to review a number of bills that impact those living with...

The FDA approved 55 new drugs in 2023 — up substantially from 2022's 37 approvals, and barely behind the all-time record of 59 set in...

Feb. 01, 2024 FOR IMMEDIATE RELEASE Washington, DC (Feb. 01, 2024) – We Work For Health has issued the following statement from Executive...

The Biden administration may soon double down on one of its gravest mistakes. In 2022, it supported a petition before the World Trade...

Today, patients in the United States have greater access to the latest lifesaving and life-altering medical treatments than anywhere...